MedTrace Logo

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

NCT04413123 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-21

No results posted yet for this study

Summary

This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.

Conditions

  • Papillary Renal Cell Carcinoma
  • Unclassified Renal Cell Carcinoma
  • Translocation Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Collecting Duct Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • Unresectable Advanced Renal Cell Carcinoma
  • Metastatic Ncc Renal Cell Carcinoma

Interventions

DRUG

Cabozantinib

Cabozantinib predetermined protocol dosage po daily

DRUG

Nivolumab

Nivolumab predetermined protocol dosage via IV every 3 weeks

DRUG

Ipilimumab

Ipilimumab predetermined protocol dosage via IV every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Bradley McGregor, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-05
Primary Completion
2026-06-20
Completion
2026-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04413123 on ClinicalTrials.gov